Interpace Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Interpace Biosciences Inc 's ROA in the second quarter of 2026?
Interpace Biosciences Inc achieved a return on average assets (ROA) of 85.91 % in its second quarter of 2026, this is above PDII's average return on assets of -16.07%.
Interpace Biosciences Inc assets over the 12 months ending in its second quarter of 2026 are valued at $28 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 11 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 36, from total ROA ranking in the first quarter of 2026 at 40.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	180.09 %	130.5 %	130.33 %	-5.59 %	7.7 %
Y / Y Net Income Change	-	-56.22 %	683.44 %	-28.83 %	-
Net Income (TTM) in million	24	24	25	5	5
Return On Assets (TTM)	85.91 %	103.25 %	135.21 %	35.93 %	38.17 %
PDII's Total Ranking	# 36	# 40	# 122	# 110	# 82
Total Assets (TTM) in million	35	33	34	12	12
Seq. Total Assets Change	3.41 %	-1.27 %	181.14 %	-2.42 %	-14.9 %
Seq. Net Income Change	-78.09 %	-96.82 %	2387.05 %	-	-

PDII's 5 Years Annual ROA >> Back to PDII Management Effectiveness >> Compare PDII ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 2
Sector	# 12
Overall	# 41

Return On Assets Statistics
High	Average	Low
135.21 %	-16.07 %	-96.66 %
(Dec 31 2025)		(Jun 30 2023)

Financial Statements
Interpace Biosciences Inc 's Assets	$ 35 million	PDII's Balance sheet
Interpace Biosciences Inc 's Income	$ 0 million	Quarterly PDII's Income Statement
PDII's Income by Division		See PDII's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	139.41 %	8.55 %	-10.17 %	-58.86 %	-16.61 %
Total Assets in million	34	14	13	14	35
Y / Y Net Income Change	266.68 %	735.66 %	-	-	-
Net Income in million	25	7	1	-22	-15
Annual Return On Assets	72.63 %	47.42 %	6.16 %	-151.49 %	-42.41 %

PDII's 5 Years Annual ROA >> Back to PDII Management Effectiveness >> Compare PDII ROA to its Competitors

Comment on PDII's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 72.63 % compared to prior year, due to annual net income growth of 266.68 % to $24.58 million, while value of Interpace Biosciences Inc 's overall assets grew just by 139.41 % to $33.84 million, compared to $33.84 a year before.

More Return On Assets Ratios
PDII's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PDII's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PDII's Competitors
Subscribers only: Roa for Interpace Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for PDII's Customers

You may also want to know
PDII's Roi	PDII's Inventory Turnover Ratio	PDII's Growth Rates	PDII's Dividend Comparisons
	PDII's Profitability Ratios	PDII's Asset Turnover Ratio	PDII's Dividend Growth
PDII's Roe	PDII's Valuation Ratios	PDII's Financial Strength Ratios	PDII's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-08-12T20:40:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.